TrialThe Journal of urology2010

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.

Matthew R Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.